Drug Profile

GMCN 508A

Alternative Names: GMCN-508A

Latest Information Update: 10 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genmedicn Biopharma
Developer Genmedicn Biopharma; The First Affiliated Hospital Of Guangxi Medical University
Class Gene therapies; Haematopoietic stem cells therapies; Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Oct 2025 GMCN 508A is still in phase I trials for Alpha-thalassaemia (In adolescents, In adults, In children) in China (Parenteral) (NCT05757245)
18 Apr 2023 Phase-I clinical trials in Alpha-thalassaemia (In adults, In children, In adolescents) in China (Parenteral) (NCT05757245)
10 Mar 2023 Preclinical trials in Alpha-thalassaemia in China (Parenteral) prior to March 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com